Filing Flows › NewAmsterdam Pharma Co N.V. (NAMS) › Q2 2026
NewAmsterdam Pharma Co N.V. (NAMS) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
NewAmsterdam Pharma Co N.V. (NAMS) reported revenue of $3.7M for the second quarter 2026 (Q2 2026), -81% from a year earlier and +22% from the quarter before.
NewAmsterdam Pharma Co N.V., Q2 2026: revenue $3.7M (-81% year over year), net loss $64.1M, operating cash flow −$39.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.7M | +22% | -81% |
| Operating profit | −$64.9M | — | — |
| Net earnings | −$64.1M | — | — |
| Operating cash flow | −$39.2M | — | — |
What changed
Revenue was $3.7M in Q2 2026, down 81% year over year and up 22% from the previous quarter.
Operating costs exceeded revenue by $64.9M, an operating margin of -1752.6%. Total costs grew 25% against a revenue fall of 81%. The fastest-growing cost line was Research & development (+51%). The quarter ended with a net loss of $64.1M, wider than the previous quarter's $48.4M loss.
Operating cash flow was −$39.2M. Non-cash charges added back $59K of depreciation and amortization and $18.4M of share-based compensation. Working capital and other items added $6.5M. Capital expenditures of $80K exceeded it, leaving free cash flow of −$39.3M.
Questions
What was NewAmsterdam Pharma Co N.V.'s revenue in the second quarter 2026?
NewAmsterdam Pharma Co N.V.